TheraRadar
Data updated: May 26, 2026

FOCALIN XR (dexmethylphenidate hydrochloride)

CNS Approved 2005-05-26

Focalin XR is a central nervous system stimulant used for Attention Deficit Hyperactivity Disorder (ADHD). It helps patients with this condition manage their symptoms and is typically prescribed for adults and children at least 6 years of age. It is not recommended for younger children because they may experience higher drug exposure and an increased risk of side effects like weight loss.

Source: FDA Label • Novartis

How FOCALIN XR Works

Focalin XR works as a central nervous system stimulant. While it is used to manage symptoms, the specific way the drug produces its therapeutic effects in patients with ADHD is currently unknown.

4
Indications
--
Phase 3 Trials
21
Years on Market

Details

Status
Prescription
First Approved
2005-05-26
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

FOCALIN XR Approval History

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
208 FDA actions from 2005 to 2025 · 1 indication expansions
Sep 2025 SUPPL
Label · Labeling
Oct 2023 SUPPL
Label · Labeling
Jun 2021 SUPPL
Label · Labeling

What FOCALIN XR Treats

1 indications

FOCALIN XR is approved for 1 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Attention Deficit Hyperactivity Disorder
Source: FDA Label

FOCALIN XR Boxed Warning

ABUSE, MISUSE, AND ADDICTION F ocalin XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin XR, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing Focalin XR, assess each patient’s risk for abuse, misuse, and addiction. Educat...

FOCALIN XR Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to FOCALIN XR

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADDERALL XR 10
AMPHETAMINE ASPARTATE
1 shared
Takeda
ADDERALL XR 15
AMPHETAMINE ASPARTATE
1 shared
Takeda
ADDERALL XR 20
AMPHETAMINE ASPARTATE
1 shared
Takeda
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FOCALIN XR FDA Label Details

Indications & Usage

FDA Label (PDF)

FOCALIN XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder.

⚠️ BOXED WARNING

WARNING: ABUSE, MISUSE, AND ADDICTION F ocalin XR has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including Focalin XR, can result in overdose and death [see Overdosage ( 10 )] , and th...

Track FOCALIN XR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.